Morgan Kohler Drug Discovery Online Articles
-
FDA's Early-Phase Solid Tumor Guidance Narrows The First-In-Human Objective
11/20/2026
The FDA has issued draft guidance telling sponsors how it wants early-phase oncology protocols written.
-
Who Gets Bench Time When Anyone Can Design A Protein?
11/19/2026
Pinal is a 16-billion-parameter foundation model that designs candidate proteins from natural-language descriptions of function.
-
A Validated Target Is No Longer A De-Risked Program
11/18/2026
Four groups are now developing degraders against the same immunology target, and none of them can differentiate on the biology.
-
Don't Discard Your Animal Data Yet
11/17/2026
Could you retrieve your historical in vivo data at the study-parameter level today, or only the reports?
-
Frontier Binder Design Just Became Free
11/16/2026
Baker institute releases first NVIDIA codeveloped protein model under an open license, shifting the bottleneck to the bench.
-
China's Proposed Technology Export Restrictions
11/13/2026
China’s Ministry of Commerce and Ministry of Science and Technology issued Joint Announcement No. 48, a draft amendment to the country’s catalog of technologies prohibited or restricted for export.
-
Rewiring BCL6 To Trigger Cell Death
11/2/2026
Shenandoah is rewiring oncogenic drivers, specifically BCL6, to bypass resistance and directly trigger the cell’s natural self-destruct machinery.
-
Finding The Therapeutic Window: Using Single-Cell Biology To Build More Selective T-Cell Engagers
10/6/2026
Cyril Konto, MD, discusses Shennon Biotechnologies programs in small cell lung cancer, ovarian cancer, and hepatocellular carcinoma, and spans antibody and TCR-based T-cell engagers.